Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 2,001–2,100 of 4,275
Exercise, healthy ageing, and the potential role of small extracellular vesicles
McIlvenna, L. C., & Whitham, M. (2022) · The Journal of Physiology · doi:10.1113/jp282468 · Cited by 28
“The systemic impact of senescent cells is considered to occur via the release of cytokines, chemokines, and other factors, termed the senescence-associated secretory phenotype (SASP) (Coppe et al., 2008).”
BackgroundWang, X., Li, N., Zheng, M., Yu, Y., & Zhang, S. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101815 · Cited by 26
Pathological implication of CaMKII in NF-κB pathway and SASP during cardiomyocytes senescence
Li, T., Meng, Y., Ding, P., Wang, H., Liu, J., Xia, C., Chen, Y., & Li, J. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111758 · Cited by 29
“Briefly, SASP is an inflammation mix secreted by senescent cells (Coppé et al., 2008).”
BackgroundTumor Suppression: p53 Alters Immune Surveillance to Restrain Liver Cancer
Raj, N., & Attardi, L. D. (2013) · Current Biology · doi:10.1016/j.cub.2013.04.076 · Cited by 27
Wang, H., Yu, Y., Li, R., Zhang, H., Chen, Z., Sun, C., & Zhuang, J. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.022 · Cited by 43
“SASP exerts anti-cancer effects in the early stages by inducing cellular senescence, activating the immune system, and promoting tissue repair, serving as an intrinsic defense mechanism to protect cells from malignant transformation 4,5 .”
InfluentialImpact of senolytic treatment on immunity, aging, and disease
Lorenzo, E. C., Torrance, B. L., & Haynes, L. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1161799 · Cited by 31
INK4a/ARF Expression Impairs Neurogenesis in the Brain of Irradiated Mice
Lê, O., Palacio, L., Bernier, G., Batinic̈‐Haberle, I., Hickson, G. R. X., & Beausejour, C. M. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.03.025 · Cited by 27
“While we cannot rule out that other secreted factors, such as CCL11, may have played a role in inhibiting neurogenesis (Lee et al., 2013; Villeda et al., 2011), our results showing that the elimination of senescent cells using GCV had no effect on neurogenesis suggest the SASP is unlikely to play a major role in IR-in…”
BackgroundInfluentialCellular Identification and Quantification of Senescence-Associated β-Galactosidase Activity In Vivo
Childs, B. G., Bussian, T. J., & Baker, D. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8931-7_4 · Cited by 29
A STAT3–STING–IFN axis controls the metastatic spread of small cell lung cancer
Guanizo, A. C., Luong, Q., Jayasekara, W. S. N., de Geus, E. D., Inampudi, C., Xue, V. S., Chen, J., de Weerd, N. A., Matthews, A. Y., Gantier, M. P., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-02014-5 · Cited by 29
“The tumor-promoting properties of cGAS–STING have been associated with the NF-κB signaling arm through the production of what has been termed the senescence-associated secretory phenotype 37,38 .”
Paluvai, H., Giorgio, E. D., & Brancolini, C. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12392 · Cited by 25
Senescence in aging and disorders of the central nervous system
Swenson, B. L., Meyer, C. F., Bussian, T. J., & Baker, D. J. (2019) · Translational Medicine of Aging · doi:10.1016/j.tma.2019.01.002 · Cited by 24
Liu, Y., Chen, L., Zhi, C., Shen, M., Sun, W., Miao, D., & Yuan, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146426 · Cited by 28
“SASP factors involving interleukins (IL-6, IL-8), growth factors (HGF), secreted proteases (MMP3) which turn senescent cells into pro-inflammatory cells can affect tissue microenvironments and stimulate tumor progression by promoting the proliferation and tumorigenesis of epithelial cells, stimulating angiogenesis, tr…”
BackgroundInfluentialQuake, S. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.03.626516 · Cited by 56
Han, Y., Zhou, C., Shen, H., Tan, J., Dong, Q. D., Zhang, L. J., McGowan, S. J., Zhao, J., Sowa, G., Kang, J. D., et al. (2020) · Aging Cell · doi:10.1111/acel.13162 · Cited by 27
“Senescent cells also can acquire a phenotype known as the senescence-associated secretory phenotype (SASP) (Coppe et al., 2008 ) whereby they secrete certain inflammatory cytokines and matrix metalloproteinases (MMPs).”
BackgroundInfluentialSenotherapeutics in Cancer and HIV
Sánchez-Díaz, L., Espinosa-Sánchez, A., Blanco, J. R., & Carnero, A. (2022) · Cells · doi:10.3390/cells11071222 · Cited by 29
“However, studies have focused on the similarities among senescent cells to target them [27,61].”
BackgroundExosome and Secretion: Action On?
Hu, Y., Zhang, R., & Chen, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_19 · Cited by 27
Transcriptional Heterogeneity of Cellular Senescence in Cancer
Junaid, M., Lee, A., Kim, J., Park, T. J., & Lim, S. B. (2022) · Molecules and Cells · doi:10.14348/molcells.2022.0036 · Cited by 27
“Studies have found that SASP factors stimulate epithelial cell invasion and EMT in tumor cells, enabling tumor cell migration and metastasis (Coppe et al., 2008; Laberge et al., 2012).”
BackgroundWei, Z., Guo, H., Qin, J., Lu, S., Liu, Q., Zhang, X., Zou, Y., Gong, Y., & Shao, C. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.457 · Cited by 24
WI-38 senescence is associated with global and site-specific hypomethylation
Sidler, C. L., Wóycicki, R. K., Kovalchuk, I., & Kovalchuk, O. (2014) · Aging · doi:10.18632/aging.100679 · Cited by 25
“On the other hand, while the pro-inflammatory microenvironment of senescent cells can contribute to the development and progression of inflammatory diseases and cancer [9, 10], the failure of senescence mechanisms can also result in malignant transformation and cancer progression [11].”
BackgroundUnraveling Adipocytes and Cancer Links: Is There a Role for Senescence?
Wu, Q., Li, B., Sun, S., & Sun, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00282 · Cited by 24
Non‐canonical ATM/MRN activities temporally define the senescence secretory program
Malaquin, N., Carrier-Leclerc, A., Martinez, A., Dessureault, M., Ghadaouia, S., Coppé, J., Nadeau, S., Cardin, G., Campisi, J., & Rodier, F. (2020) · EMBO Reports · doi:10.15252/embr.202050718 · Cited by 29
“Alternatively, we exposed these cells to a single dose of 10 Gray (Gy) XRA, which is known to trigger a full senescence program associated with persistent DDR signaling and DNA-SCARS (Coppe et al , 2008; Rodier et al , 2009, 2011).”
InfluentialSelf-citationHypoxia and gerosuppression: The mTOR saga continues
Leontieva, O. V., & Blagosklonny, M. V. (2012) · Cell Cycle · doi:10.4161/cc.21908 · Cited by 29
“And hyper-secretory phenotype or senescence-associated secretory phenotype (SASP) is one of the hallmarks of cellular senescence.(2-5) Possibly, while inducing some manifestations of senescence such as secretory Hypoxia and gerosuppression”
BackgroundSenescent Stromal Cells in the Tumor Microenvironment: Victims or Accomplices?
Ye, M., Huang, X., Wu, Q., & Liu, F. (2023) · Cancers · doi:10.3390/cancers15071927 · Cited by 29
“SASP is defined as a collective term for pro-inflammatory cytokines, growth factors, and extracellular modifiers secreted by senescent cells [19,20].”
BackgroundExercise Training for the Elderly: Inflammaging and the Central Role for HSP70
Muller, C. H. D. L., de Matos, J. R., Grigolo, G. B., Schroeder, H. T., Rodrigues-Krause, J. D. C., & Krause, M. D. S. (2019) · Journal of Science in Sport and Exercise · doi:10.1007/s42978-019-0015-6 · Cited by 29
Role of cellular senescence in hepatic wound healing and carcinogenesis
Ramakrishna, G., Anwar, T., Angara, R. K., Chatterjee, N., Kiran, S., & Singh, S. (2012) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2012.08.002 · Cited by 23
Ishaq, A., Schröder, J., Edwards, N., von Zglinicki, T., & Saretzki, G. C. (2017) · The journal of nutrition health & aging · doi:10.1007/s12603-017-0968-2 · Cited by 27
Cell senescence, the senescence-associated secretory phenotype, and cancers
Prata, L. G. P. L., Tchkonia, T., & Kirkland, J. L. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002326 · Cited by 29
“The discovery of senolytics [9] was enabled by 3 observations: the finding that senescent cells are relatively resistant to programmed cell death (apoptosis) by Eugenia Wang in 1995 [10]; studies by Norman Sharpless and colleagues in 2004 [11] that associated increases in healthspan with reduced age-related senescent…”
BackgroundInfluentialMechanisms of Senescence and Anti-Senescence Strategies in the Skin
Konstantinou, E. K., Longange, E., & Kaya, G. (2024) · Biology · doi:10.3390/biology13090647 · Cited by 35
Toll-like receptor 2 orchestrates a tumor suppressor response in non-small cell lung cancer
Millar, F. R., Pennycuick, A., Muir, M., Quintanilla, A., Hari, P., Freyer, E., Gautier, P. E., Meynert, A. M., Grimes, G. R., Salomo-Coll, C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111596 · Cited by 32
Oh, S., Park, S., Lee, K.-W., Madhi, H., Park, S. G., Lee, H. G., Cho, Y., Yoo, J., & Kim, K. D. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.153 · Cited by 27
“tion of senescence-associated β-galactosidase (SA-β-gal) activity(23) and adoption of a senescence-associated secretory phenotype (SASP).(24) Generally, cancer cells avoid cellular”
BackgroundTargeting Cellular Senescence with Senotherapeutics: Development of New Approaches for Skin Care
Thompson, E. L., Pitcher, L. E., Niedernhofer, L. J., & Robbins, P. D. (2021) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000009668 · Cited by 29
The diet-microbiota-metabolite axis regulates the host physiology
Yamada, T., Takahashi, D., & Hase, K. (2016) · The Journal of Biochemistry · doi:10.1093/jb/mvw022 · Cited by 30
“This phenotypic change facilitates hepatic inflammation and tumorigenesis by upregulating SASP factors including interleukin (IL)-1, IL-6, and plasminogen activator inhibitor-1 (30).”
BackgroundSenescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment
Zhang, T., Zhang, J., Lv, C., Li, H., & Song, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1059434 · Cited by 29
“Proinflammatory and matrix-degradation factors are the most important ones (Coppe et al., 2008).”
BackgroundWang, Y., Xu, Q., Sack, L. M., Kang, C., & Elledge, S. J. (2016) · Genes & Development · doi:10.1101/gad.271445.115 · Cited by 24
“This phenomenon is referred to as the Senescence- Associated Secretory Phenotype (SASP) [80] [84] or”
BackgroundThe impact of cellular senescence in cancer therapy: is it true or not?
Zhang, Y., & Yang, J. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.108 · Cited by 30
Basu, D., Reyes‐Múgica, M., & Rebbaa, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052188 · Cited by 27
“In fact, it is now recognized that among the prominent senescence-associated changes in gene expression, there is a robust increase in the synthesis and secretion of numerous cytokines, chemokines, growth factors and proteases [6,8,9], a phenomenon termed senescence-associated secretory phenotype (SASP) [10].”
BackgroundAdmasu, T. D., & Yu, J. S. (2025) · Aging Cell · doi:10.1111/acel.70055 · Cited by 32
“The SASP factors may also be important mediators of the pro-tumorigenic effects of senescent cells by creating a chronic inflammatory microenvironment that supports cancer growth (Coppé et al. 2008; Lasry and Ben-Neriah 2015).”
Adrados, I., Larrasa-Alonso, J., Galarreta, A., López‐Antona, I., Menéndez, C., Abad, M., Gil, J., Moreno‐Bueno, G., & Palmero, I. (2015) · Oncogene · doi:10.1038/onc.2015.408 · Cited by 25
Graves, S. I., Meyer, C. F., Jeganathan, K. B., & Baker, D. J. (2025) · Neuron · doi:10.1016/j.neuron.2025.04.020 · Cited by 27
Chen, Z., Chen, C., Yang, X. F., Zhou, Y., Cao, X., Chen, H., Zhou, T., Zhao, J., & Qin, A. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.88534 · Cited by 29
“Genomic instability is a hallmark of age-related diseases with increased DNA damage considered a major instigator of cellular senescence and abnormal expression of inflammatory cytokines, a phenotype described as senescence-associated secretory phenotype (SASP) [10].”
BackgroundGenetic origins, regulators, and biomarkers of cellular senescence
Torres, G., Salladay-Perez, I. A., Dhingra, A., & Covarrubias, A. J. (2024) · Trends in Genetics · doi:10.1016/j.tig.2024.08.007 · Cited by 25
Autophagy-independent senescence and genome instability driven by targeted telomere dysfunction
Mar, F. A., Debnath, J., & Stohr, B. A. (2015) · Autophagy · doi:10.1080/15548627.2015.1017189 · Cited by 25
Prospects of Disease-Modifying Osteoarthritis Drugs
Oo, W. M. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.11.010 · Cited by 28
Effects of Ginger (Zingiber officinale) on the Hallmarks of Aging
Matin, M., Joshi, T., Wang, D., Tzvetkov, N. T., Matin, F. B., Wierzbicka, A., Jóźwik, A., Horbańczuk, J. O., & Atanasov, A. G. (2024) · Biomolecules · doi:10.3390/biom14080940 · Cited by 33
“Apart from inducing a persistent growth arrest in stem cells, senescence can also disrupt the local stem-cell niche through the secretion of a group of pro-inflammatory and pro-growth factors known as the Senescence Associated Secretory Phenotype (SASP) [145] or Senescence Messaging Secretome [146].”
BackgroundWallis, R., Josipović, N., Mizen, H., Robles‐Tenorio, A., Tyler, E. J., Papantonis, A., & Bishop, C. L. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12041 · Cited by 25
“These pathologies are driven by the acquisition of an enhanced secretome comprising inflammatory cytokines, chemokines, growth factors and proteases – the senescence-associated secretory phenotype (SASP) (Coppé et al., 2008; Coppé et al., 2010).”
BackgroundWrench, C., Baker, J. R., Monkley, S., Fenwick, P. S., Murray, L. A., Donnelly, L., & Barnes, P. J. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00419.2022 · Cited by 32
Role of accelerated aging in limb muscle wasting of patients with COPD
Lakhdar, R., McGuinness, D., Drost, E., Shiels, P. G., Bastos, R., MacNee, W., & Rabinovich, R. (2018) · International Journal of COPD · doi:10.2147/copd.s155952 · Cited by 25
“chemokines as part of the senescence-associated secretory phenotype (SASP).(19) These alter the tissue microenviron-”
BackgroundDespres, J., Ramdani, Y., Giovanni, M. D., Bénard, M., Zahid, A., Montero‐Hadjadje, M., Yvergnaux, F., Saguet, T., Driouich, A., & Follet‐Gueye, M. (2019) · Experimental Dermatology · doi:10.1111/exd.13886 · Cited by 26
Wei, Z., Liang, C., Feng, D., Cheng, Y., Wang, W., Yang, D., Wang, Y., & Cai, Q. (2016) · Oncotarget · doi:10.18632/oncotarget.7397 · Cited by 26
“In the process of inflammation, IL-6 and IL-8 can further strengthen the inflammatory response and induce the production of additional inflammatory cytokines [26].”
BackgroundApoptosis Regulation in Osteoarthritis and the Influence of Lipid Interactions
Werry, F., Mazur, E. M., Theyse, L. F. H., & Edlich, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713028 · Cited by 28
“In particular, inflammatory cytokines are the likely culprits for the induction of apoptosis in OA [94].”
BackgroundProteomic assessment of serum biomarkers of longevity in older men
ORWOLL, E. S., Wiedrick, J. T., Nielson, C. M., Jacobs, J., Baker, E. S., Piehowski, P., Petyuk, V., Gao, Y., Shi, T., Smith, R. D., et al. (2020) · Aging Cell · doi:10.1111/acel.13253 · Cited by 23
“…(SERPINA3), (SERPINF1), (SPARC), (TGFBI) Table 4 (Continued) being part of the senescence-associated secretory phenotype (SASP) (Basisty et al., 2020; Coppe et al., 2008; Matjusaitis et al., 2016), deleterious products released by senescent cells that accumulate with aging (van Deursen, 2014;…”
BackgroundMolecular constraints of sarcopenia in the ageing muscle
Damanti, S., Senini, E., LORENZO, R. D., Merolla, A., Santoro, S., Festorazzi, C., Messina, M., Vitali, G., Sciorati, C., Manfredi, A. A., et al. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1588014 · Cited by 36
Senescence chips for ultrahigh‐throughput isolation and removal of senescent cells
Chen, Y., Mao, P., Snijders, A. M., & Wang, D. (2018) · Aging Cell · doi:10.1111/acel.12722 · Cited by 25
“Scale bars represent 10 mm in (b) and 50 lm in (d) phenotype (SASP) (Cashen, Link, Devine & DiPersio, 2004; Coppe et al., 2008; Pitchford, Furze, Jones, Wengner & Rankin, 2009; Rodier et al., 2009).”
BackgroundKaverina, N. V., Григорьевна, К. З., Borovjagin, A. V., Karseladze, A. I., Kim, C. K., Lesniak, M. S., Miska, J. M., Zhang, P., Baryshnikova, M. A., Xiao, T., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0395-9 · Cited by 24
Role of galactose in cellular senescence
Elzi, D. J., Song, M., & Shiio, Y. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2015.11.003 · Cited by 24
Clinical validation of C 12 FDG as a marker associated with senescence and osteoarthritic phenotypes
Hambright, W. S., Duke, V. R., Goff, A. D., Goff, A., Minas, L. T., Kloser, H., Gao, X., Huard, C., Guo, P., Lu, A., et al. (2024) · Aging Cell · doi:10.1111/acel.14113 · Cited by 23
“Cellular senescence and the release of pro-inflammatory cytokines/chemokines, proteases, and other factors collectively referred to as senescence-associated secretory phenotype (SASP) (Coppe et al., 2008; Tchkonia & Kirkland, 2018) have been described for their ability to induce OA (Xu et al., 2017).”
BackgroundInfluentialSGLT2 inhibitors as a novel senotherapeutic approach
Yeşilyurt, Z. E., Qi, C., Wang, Y.-C., Simm, A., Deelen, L., Gasim, A. H. A., Lewis, F., & Ellison, G. M. (2025) · npj Aging · doi:10.1038/s41514-025-00227-y · Cited by 33
Zhang, J., Zhang, S., Cheng, C., Zhu, C., Wang, T., Tang, L., Lou, J., Li, X., Wang, H. R., Hu, F., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122915 · Cited by 28
Understanding cellular senescence: pathways involved, therapeutics and longevity aiding
Kumar, A., & Thirumurugan, K. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2287929 · Cited by 31
The tumor suppression theory of aging
Wolf, A. M. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111583 · Cited by 30
“The possibly vicious circle of ubiquitous senescence, widespread SASP and chronic inflammation might be an evolutionary accident brought about by the unforeseen, unprecedented surge in human longevity.”
BackgroundInfluentialUnbalanced Growth, Senescence and Aging
Polymenis, M., & Kennedy, B. K. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57127-0_8 · Cited by 26
Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema
Klier, S. M., Dananberg, J., Masaki, L., Bhisitkul, R. B., Khanani, A. M., Maturi, R. K., Salehi-Had, H., Mallinckrodt, C. H., Rathmell, J. M., Ghosh, A., et al. (2025) · NEJM Evidence · doi:10.1056/evidoa2400009 · Cited by 27
New Horizons in cellular senescence for clinicians
Witham, M. D., Granic, A., Miwa, S., Passos, J. F., Richardson, G. D., & Sayer, A. A. (2023) · Age and Ageing · doi:10.1093/ageing/afad127 · Cited by 26
“This phenotype contributes to tissue dysfunction, driving chronic inflammation and promoting tissue remodelling [8].”
BackgroundMolecules of senescent glial cells differentiate Alzheimer’s disease from ageing
Dai, L., Gao, F., Wang, Q., Lv, X., Cheng, Z., Wu, Y., Chai, X., Zetterberg, H., Blennow, K., Levey, A. I., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330743 · Cited by 29
Senescence and Aging: Does It Impact Cancer Immunotherapies?
Maggiorani, D., & Beausejour, C. M. (2021) · Cells · doi:10.3390/cells10071568 · Cited by 25
Jumonji C Demethylases in Cellular Senescence
Leon, K. E., & Aird, K. M. (2019) · Genes · doi:10.3390/genes10010033 · Cited by 22
“In addition to the cell cycle arrest, senescence is also often defined by the SASP [78].”
BackgroundThe potential of Senolytics in transplantation
Matsunaga, T., Iske, J., Schroeter, A., Azuma, H., Zhou, H., & Tullius, S. G. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111582 · Cited by 22
Reflections on the role of senescence during development and aging
Triana-Martínez, F., Pedraza-Vázquez, G., Maciel-Barón, L. Á., & Königsberg, M. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.04.004 · Cited by 24
Iscador Qu inhibits doxorubicin-induced senescence of MCF7 cells
Srdić‐Rajić, T., Santibanez, J. F., Kanjer, K., Miletić, N. T., Cavic, M. R., Galun, D., Jevric, M., Kardum, N., Konić‐Ristić, A., & Zoranovic, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-03898-0 · Cited by 25
Lugo, R., Gabasa, M., Andriani, F., Puig, M., Facchinetti, F., Ramírez, J., Gómez-Caro, A. A., Pastorino, U., Fuster, G., Almendros, I., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10327 · Cited by 24
“Cancer cell invasion was assessed with a slightly modified Transwell-based assay [37], and performed with Transwell culture plates with filter-inserts (24 Transwell plate, 8 μm filter pore size; Merck Millipore).”
BackgroundMethodAdvances of Genome Editing with CRISPR/Cas9 in Neurodegeneration: The Right Path towards Therapy
Klinkovskij, A., Shepelev, M. V., Isaakyan, Y. A., Aniskin, D., & Ulasov, I. V. (2023) · Biomedicines · doi:10.3390/biomedicines11123333 · Cited by 27
Centrosome instability: when good centrosomes go bad
Ryniawec, J. M., & Rogers, G. C. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03928-1 · Cited by 28
Adipose Tissue Compartments, Inflammation, and Cardiovascular Risk in the Context of Depression
Stapel, B., Jelinic, M., Drummond, G. R., Hartung, D., & Kahl, K. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.831358 · Cited by 28
Hoare, M., & Narita, M. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-89512-3_15 · Cited by 24
Shining the Light on Senescence Associated LncRNAs
Ghanam, A. R., Xu, Q., Ke, S., Azhar, M., Cheng, Q., & Song, X. (2017) · Aging and Disease · doi:10.14336/ad.2016.0810 · Cited by 25
“A major consequence of these changes is the secretion of many factors, including cytokines and chemokines, growth factors, proteases [4, 32-35], and SAβ-gal [12], which partly reflects the increase in lysosomal mass [36] as well as p16, which also is not commonly expressed by quiescent or terminally differentiated cel…”
Mesenchymal Stem Cell Senescence and Osteogenesis
Tjempakasari, A., Suroto, H., & Santoso, D. (2021) · Medicina · doi:10.3390/medicina58010061 · Cited by 29
“FOXOs play an essential role in bone turnover and osteoclast activation by decreasing the ROS substance [59].”
BackgroundAndriani, G. A., Maggi, E. C., Piqué, D. G., Zimmerman, S. E., Lee, M., Quispe‐Tintaya, W., Maslov, A. Y., Campisi, J., Vijg, J., Mar, J. C., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46606-w · Cited by 25
Self-citationAdipose tissue and age‑dependent insulin resistance: New insights into WAT browning (Review)
Wu, C., Yu, P., & Sun, R. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4904 · Cited by 25
“In addition, during hyper‐ trophy, adipocytes present in the senescent state and secrete a multitude of growth factors, cytokines, matrix metalloprotein‐ ases and chemokines (47).”
BackgroundSenescent cells: A new Achilles’ heel to exploit for cancer medicine?
Zhang, B., Lam, E. W. ‐., & Sun, Y. (2018) · Aging Cell · doi:10.1111/acel.12875 · Cited by 24
Self-citationInnate immunity dysregulation in aging eye and therapeutic interventions
Das, S., Ahmad, Z., Suryawanshi, A. S., & Kumar, A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101768 · Cited by 25
Ask, T. F., Lugo, R. G., & Sütterlin, S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00726 · Cited by 24
“This can potentially increase false positives, and multimarker approaches has received favorable appraise (Narita et al., 2003; Coppé et al., 2008; Shimi et al., 2011; Hewitt et al., 2012).”
BackgroundInfluentialInduction, regulation and roles of neural adhesion molecule L1CAM in cellular senescence
Mrázková, B., Dzijak, R., Hornofova, T., Kyjacová, L., Baráth, P., Džubák, P., Holub, D., Hajdúch, M., Nahácka, Z., Anděra, L., et al. (2018) · Aging · doi:10.18632/aging.101404 · Cited by 29
“The composition of the SC secretome (denoted as senescence-associated secretory phenotype; SASP) varies according to the cell type and mechanism of senescence induction [14].”
BackgroundSenescence and Type 2 Diabetic Cardiomyopathy: How Young Can You Die of Old Age?
Henson, S. M., & Aksentijević, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.716517 · Cited by 25
“Despite the inability to divide, senescent cells maintain high metabolic activity supporting the secretion of growth factors, proinflammatory cytokines, chemokines, angiogenetic factors, and matrix metalloproteinases collectively defined as the SenescenceAssociated Secreting Phenotype or SASP (Coppé et al., 2008; Kuil…”
BackgroundRole of melanoma inhibitory activity in melanocyte senescence
Feuerer, L., Lamm, S., Henz, I., Kappelmann‐Fenzl, M., Haferkamp, S., Meierjohann, S., Hellerbrand, C., Kuphal, S., & Bosserhoff, A. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12801 · Cited by 39
“This property is termed the senescence‐associ‐ ated secretory phenotype (SASP) and the senescence‐messaging secretome (SMS) (Campisi, 2005a; Coppe et al., 2008; Kuilman & Peeper, 2009).”
BackgroundMavrogonatou, E., Papadopoulou, A., Fotopoulou, A., Tsimelis, S., Bassiony, H., YIACOUMETTIS, A. M., Panagiotou, P. N., Pratsinis, H., & Kletsas, D. (2021) · Cancers · doi:10.3390/cancers13081987 · Cited by 25
“Nevertheless, although the implication of soluble SASP constituents and proteolytic enzymes in tissue remodeling has been thoroughly investigated [63,64], the study of the role of insoluble SASP factors, such as ECM components, has lagged behind.”
BackgroundMartino, M. D., Tkach, M., Bruni, S., Rocha, D., Mercogliano, M. F., Cenciarini, M. E., Chervo, M. F., Proietti, C. J., Dingli, F., Loew, D., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1715767 · Cited by 24
The interplay between cell death and senescence in cancer
Shimizu, K., Inuzuka, H., & Tokunaga, F. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.11.001 · Cited by 30
Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes
Gaiani, F., Marchesi, F., Negri, F., Greco, L., Malesci, A., de’Angelis, G. L., & Laghi, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105246 · Cited by 30
Exploiting cellular senescence to treat cancer and circumvent drug resistance
Yan, Q., & Wajapeyee, N. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.3.11166 · Cited by 24
Senescence in chronic allograft nephropathy
Peña, M. D. P. S., Lopez‐Soler, R. I., & Melendez, J. A. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00195.2016 · Cited by 26
“The 244 SASP has been shown to promote cell proliferation and cell motility in tumor 245 cells, to regulate cell differentiation in epithelial and endothelial cells, and to 246 affect leukocyte infiltration (24, 25).”
BackgroundThe impact of age on oncogenic potential: tumor-initiating cells and the brain microenvironment
Stoll, E. A., Horner, P. J., & Rostomily, R. (2013) · Aging Cell · doi:10.1111/acel.12104 · Cited by 26
“NF1 inhibits RAS activity, while PTEN dephosphorylates phosphotidylinositol-3,4,5trisphosphate; both thereby inhibit the downstream phosphorylation of Akt.”
BackgroundInfluentialSenescence and senolysis in cancer: The latest findings
Imawari, Y., & Nakanishi, M. (2024) · Cancer Science · doi:10.1111/cas.16184 · Cited by 26
“4 The increased tumor vascularization observed when tumorigenic epithelial cells and senescent fibroblasts were coinjected subcutaneously into mice suggests that senescence may promote tumorigenesis by stimulating angiogenesis.”
BackgroundThe Chronic Lymphocytic Leukemia Clone Disrupts the Bone Marrow Microenvironment
Janel, A., Dubois-Galopin, F., Bourgne, C., Berger, J., Tarte, K., Boiret‐Dupré, N., Boisgard, S., Verrelle, P., Déchelotte, P., Tournilhac, O., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0229 · Cited by 23
“…genes, that is, VEGF, IL-6, IGFBP2, and SPARC have been included in the recently described senescence-associated secretor phenotype (SASP) [24], we analyzed the capacity of CLL-MSC to secrete molecules corresponding to some of our up-regulated genes and others included in SASP and/or in…”
An update in toxicology of ageing
Račková, L., Mach, M., & Brnoliaková, Z. (2021) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2021.103611 · Cited by 24
Chao, S. K., Lin, J., Brouwer‐Visser, J., Smith, A. B., Horwitz, S. B., & McDaid, H. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016962108 · Cited by 23
Telomeres: Dysfunction, Maintenance, Aging and Cancer
Liao, P., Yan, B., Wang, C., & Lei, P. (2023) · Aging and Disease · doi:10.14336/ad.2023.1128 · Cited by 36
“First, telomere disruption causes cellular senescence, which increases the synthesis and release of inflammatory mediators such as TNF-α and IL-6 [16,117,119].”
Novel perspectives on leptin in osteoarthritis: Focus on aging
Liu, Z., Xie, W., Li, H., Liu, X., Lu, Y., Lu, B., Deng, Z., & Li, Y. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101159 · Cited by 37
Yang, H. H., Kim, C., Jung, B., Kim, K. S., & Kim, J.-R. (2011) · Biogerontology · doi:10.1007/s10522-010-9318-z · Cited by 22
“1f, 4a) and forskolin (Fig. 4b), (ii) IGFBP5 expression is repressed by EP1 and EP4 antagonists (Fig. 2c), and (iii) PGE2-induced cellular senescence is inhibited by IGFBP5 knockdown (Fig. 6b, c). A variety of secretory molecules associated with inflammation, such as IGFBPs, interferons, interleukins, and transforming…”
BackgroundNiklander, S. E., Crane, H. L., Darda, L., Lambert, D., & Hunter, K. D. (2021) · Journal of Cell Science · doi:10.1242/jcs.252080 · Cited by 23
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.